CP-751,871
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing's Sarcoma Family of Tumors
Conditions
Ewing's Sarcoma Family of Tumors
Trial Timeline
Mar 1, 2008 → Oct 1, 2012
NCT ID
NCT00560235About CP-751,871
CP-751,871 is a phase 1/2 stage product being developed by Pfizer for Ewing's Sarcoma Family of Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00560235. Target conditions include Ewing's Sarcoma Family of Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00560235 | Phase 1/2 | Completed |
| NCT00474760 | Phase 1 | Completed |
| NCT01536145 | Phase 1 | Completed |
Competing Products
3 competing products in Ewing's Sarcoma Family of Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 52 |
| CP-751,871 | Pfizer | Phase 1 | 32 |
| plerixafor + plerixafor + plerixafor | Sanofi | Phase 1/2 | 40 |